ロード中...

Immune Checkpoint Inhibitors and Immune-Related Adverse Drug Reactions: Data From Italian Pharmacovigilance Database

BACKGROUND: The introduction of immune checkpoint inhibitors (ICIs) in clinical practice has brought significant benefits for patients. Seven ICIs are available in Europe: nivolumab, pembrolizumab, atezolizumab, avelumab, durvalumab, cemiplimab, and ipilimumab. Despite their proven clinical efficacy...

詳細記述

保存先:
書誌詳細
出版年:Front Pharmacol
主要な著者: Ruggiero, Rosanna, Fraenza, Federica, Scavone, Cristina, di Mauro, Gabriella, Piscitelli, Raffaele, Mascolo, Annamaria, Ferrajolo, Carmen, Rafaniello, Concetta, Sportiello, Liberata, Rossi, Francesco, Capuano, Annalisa
フォーマット: Artigo
言語:Inglês
出版事項: Frontiers Media S.A. 2020
主題:
オンライン・アクセス:https://ncbi.nlm.nih.gov/pmc/articles/PMC7295943/
https://ncbi.nlm.nih.gov/pubmed/32581796
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3389/fphar.2020.00830
タグ: タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!